Evaluation of the efficacy of Methylphenidate and modafinil in the treatment of excessive daily sleepiness in patients with drug-resistant epilepsy and comparison with the control group

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20171030037093N22

Enrollment

Registered

2019-10-18

Start date

2019-10-25

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy. Epilepsy and recurrent seizures

Interventions

Intervention 1: Intervention group: The first group will be treated with methylphenidate at 10-20-day / mg. Intervention 2: Intervention group: Group II treated with modafinil at a dose of 200–600 mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: People with refractory epilepsy Diagnosis of EDS by a neurologist Hypersensitivity to methylphenidate and modafinil Individual consent to participate in the study

Exclusion criteria

Exclusion criteria: Head trauma Diagnosis of other neurologic diseases such as dementia stroke Thyroid diseases Drug abuse Liver or kidney failure

Design outcomes

Primary

Measure	Time frame
The amount of drowsiness. Timepoint: Before and after treatment. Method of measurement: questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammadreza Najafi

Esfahan University of Medical Sciences

najafi@med.mui.ac.ir+98 31 3668 5555

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026